Qiagen Collaborates with Institut Curie to Develop High-Throughput RNAi Tools
News Oct 13, 2005
Qiagen and Institut Curie have announced a collaboration to develop tools for high-throughput RNAi screening as part of the Institut Curie BioPhenics project.
This project, led by Drs Jacques Camonis and Franck Perez, aims to use RNAi technology in conjunction with advanced systematic phenotypic analysis to accelerate cancer drug discovery.
“As one of the largest cancer research centers in Europe, part of the ongoing research at Institut Curie is dedicated to the understanding of how cells become cancerous,” said Jacques Camonis, head of the BioPhenics project in the Translational Department at Institut Curie.
“The goal of the 'BioPhenics' project is to apply cell biology and microscopic imaging to cancer research for a deeper understanding, improved target validation and, ultimately, more efficient cancer drug discovery.”
“Qiagen is pleased to be able to contribute to this ambitious and exciting research,” said Jie Kang, V.P. of R & D at Qiagen.
“The combination of Qiagen advanced siRNA design and extremely efficient HiPerFect delivery reagent should contribute greatly to the overall goals of the project.”
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018